151 related articles for article (PubMed ID: 21138499)
1. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis.
Wang J; Jin D; Zuo P; Wang T; Xu Y; Xiong W
Respirology; 2011 Feb; 16(2):350-8. PubMed ID: 21138499
[TBL] [Abstract][Full Text] [Related]
2. Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease.
Tashkin DP; Hanania NA; McGinty J; Denis-Mize K; Chaudry I
Adv Ther; 2009 Nov; 26(11):1024-34. PubMed ID: 19953349
[TBL] [Abstract][Full Text] [Related]
3. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study.
Di Marco F; Verga M; Santus P; Morelli N; Cazzola M; Centanni S
Respir Med; 2006 Nov; 100(11):1925-32. PubMed ID: 16626956
[TBL] [Abstract][Full Text] [Related]
4. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
[TBL] [Abstract][Full Text] [Related]
5. Bronchodilator efficacy of tiotropium-formoterol via single pressurized meter dose inhaler (pMDI) versus tiotropium alone in COPD.
Salvi S; Brashier B; Gothi D; Karkhanis V; Madas S; Gogtay J; Joshi J
Pulm Pharmacol Ther; 2014 Feb; 27(1):90-5. PubMed ID: 23752057
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
Hanania NA; Boota A; Kerwin E; Tomlinson L; Denis-Mize K
Drugs; 2009 Jun; 69(9):1205-16. PubMed ID: 19537837
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of tiotropium in Chinese patients with stable chronic obstructive pulmonary disease: a meta-analysis.
Wu Q; Li G; Lei WI; Zhou X
Respirology; 2009 Jul; 14(5):666-74. PubMed ID: 19402836
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium plus formoterol versus tiotropium alone for stable moderate-to-severe chronic obstructive pulmonary disease: A meta-analysis.
Zou Y; Xiao J; Lu XX; Xia ZA; Xie B; Li J; Chen Q
Clin Respir J; 2018 Jan; 12(1):269-278. PubMed ID: 27402142
[TBL] [Abstract][Full Text] [Related]
9. Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis.
Tian JW; Chen JW; Chen R; Chen X
Respir Care; 2014 May; 59(5):654-66. PubMed ID: 24170916
[TBL] [Abstract][Full Text] [Related]
10. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.
van Noord JA; Aumann JL; Janssens E; Verhaert J; Smeets JJ; Mueller A; Cornelissen PJ
Chest; 2006 Mar; 129(3):509-17. PubMed ID: 16537846
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
[TBL] [Abstract][Full Text] [Related]
12. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Sobieraj DM; White CM; Coleman CI
Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
[TBL] [Abstract][Full Text] [Related]
13. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.
Tashkin DP; Donohue JF; Mahler DA; Huang H; Goodwin E; Schaefer K; Hanrahan JP; Andrews WT
Respir Med; 2009 Apr; 103(4):516-24. PubMed ID: 19208459
[TBL] [Abstract][Full Text] [Related]
14. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
[TBL] [Abstract][Full Text] [Related]
15. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
[TBL] [Abstract][Full Text] [Related]
16. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
Bölükbas S; Eberlein M; Eckhoff J; Schirren J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
[TBL] [Abstract][Full Text] [Related]
17. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD.
Richter K; Stenglein S; Mücke M; Sieder C; Schmidtmann S; Harnest U; Weidinger G; Magnussen H
Respiration; 2006; 73(4):414-9. PubMed ID: 16534180
[TBL] [Abstract][Full Text] [Related]
18. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease.
Karner C; Cates CJ
Cochrane Database Syst Rev; 2012 Apr; 4(4):CD008989. PubMed ID: 22513969
[TBL] [Abstract][Full Text] [Related]
19. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.
Tashkin DP; Pearle J; Iezzoni D; Varghese ST
COPD; 2009 Feb; 6(1):17-25. PubMed ID: 19229704
[TBL] [Abstract][Full Text] [Related]
20. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]